Michael J Sofia, Ph.D.
Michael J. Sofia, Ph.D. is currently President and Co-Founder of OnCore Biopharma, Inc. a company focused on the discovery and development of therapies to treat liver and viral diseases. He also holds a professorship at the Institute for Hepatology and Virus Research, The Pennsylvania Commonwealth Institute.
Mike Sofia was Senior Vice President of Chemistry, Princeton Site Head and Senior Advisor at Gilead Sciences from Jan 2012 to Dec 2012. Previously he was Sr. Vice President of Chemistry at Pharmasset, Inc (Aug 2005 – Jan 2012) until Pharmasset’s acquisition by Gilead in Jan 2012. At Pharmasset he had responsibility for research strategy, medicinal chemistry, process research, computational chemistry and analytical chemistry functions and was a clinical development project leader. He is the inventor of Sofosbuvir for the treatment of HCV infection.
Mike Sofia held the position of Group Director New Leads Chemistry at Bristol-Myers Squibb where he had global responsible for Lead Discovery. Prior to joining BMS, he was Vice President of Research at Intercardia Research Labs (formerly Transcell Technologies) where he directed research in the areas of infectious diseases drug discovery and combinatorial chemistry technology development. He also held research and project leader positions at Lilly Research Labs, Eli Lilly & Co. and at the Squibb Institute for Medical Research E. R. Squibb.
Mike Sofia received his B.A. degree in chemistry from Cornell University, his Ph.D. from the University of Illinois, Urbana-Champaign and was an NIH postdoctoral fellow at Columbia University.
Mike Sofia is on the editorial boards ofInfectious Diorders: Drug Targets, Expert Opinion on Drug Discovery and Organic and Medicinal Chemistry Letters. He has authored 93 publications, 8 book chapters and numerous abstracts and is an inventor on over 30 patents and patent applications. He has been an invited speaker at numerous national and international conferences.